Buz Investors InMed Pharmaceuticals ("InMed") (CSE: IN; OTCQB: IMLFF) announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference,

InMed Pharmaceuticals, Inc. (IMLFF) Announces Publication in European Journal of Pain

InMed Announces Publication in European Journal of Pain

InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research

InMed Pharmaceuticals, Inc PRESS RELEASE . (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the publication of company-sponsored research in the European Journal of Pain.  The article, titled “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation”, presents results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship program. The study was conducted by Dr. Hayes Wong and Prof. Brian Cairns at the University of British Columbia and was co-authored by Dr. Sazzad Hossain , Chief Scientific Officer of InMed.
The study results suggest that peripheral application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) may provide a valuable approach in treating severe pain.  The model utilized in this study mimics muscle pain reported by sufferers of temporomandibular disorders (TMD) that affect the jaw muscles and joint.  TMD is a chronic pain condition that is difficult to treat with current pain-relieving medications and more commonly affects women than men.



InMed Pharmaceuticals

“Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the ‘holy grails’ in the field of analgesia”, said Dr. Sazzad Hossain , CSO of InMed.  “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”

Use of InMed’s proprietary bioinformatics database assessment tool has led to the identification of several individual cannabinoid compounds, or combinations thereof, to specifically address both chronic and acute pain in a topically-applied product.  “InMed’s internal targeting capabilities, linking specific cannabinoids to diseases with a high unmet medical need, remains a fundamental component to our ongoing success in validating the role of this class of compounds in a wide range of diseases”, added Dr. Hossain.

 

For additional information, please follow this link to the article:

http://onlinelibrary.wiley.com/doi/10.1002/ejp.1085/full

About Mitacs

Mitacs Elevate helps organizations develop their research & development management capacity in-house with a minimal impact on their R&D budgets. By connecting companies with a talented PhD graduates, the two-year research project encourages knowledge transfer of the fellow’s practical and professional skills to the organization. These collaborations help build research and development management capacity and companies benefit from fellows’ creativity and fresh approach to current research challenges.

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



BUZ INVESTORS Proposed Cannabis Legislation Lexaria Bioscience Corp (LXRP)(CSE:LXX) (the “Company”, “Lexaria”) welcomes the newly proposed Canadian legislation designed

Lexaria Bioscience Corp. (LXRP) Announces Publication Highlighting the Operations of Several Public Cannabis-Biotech Companies

NetworkNewsWire Announces Publication Highlighting the Operations of Several Public Cannabis-Biotech Companies

Lexaria Bioscience  NetworkNewsWire (“NNW”), a multifaceted financial news and publishing
Lexaria Bioscience  PRESS RELEASE NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. ( CSE : LXX ) ( OTCQB : LXRP ), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids.
The publication, entitled, “Biotech Players Lead the Growth Charge in the Legal Cannabis Market,” discusses five companies that are targeting areas of unmet medical need through cannabis-based therapies.

To view the full publication, visit: https://www.networknewswire.com/biotech-players-lead-growth-charge-legal-cannabis-market/

“Food bioscience company Lexaria Bioscience Corp. ( OTCQB : LXRP ) ( CSE : LXX ), for instance, enjoys a unique position in this sub-sector. As the only publicly traded company with a cannabis-based intellectual portfolio that includes NSAIDs, nicotine and vitamins, Lexaria has multiple patents pending in over 40 countries, and it recently received its first patents in the U.S. and Australia relating to edible forms of cannabinoids (http://nnw.fm/e8LvY).



Lexaria Bioscience

“Lexaria Energy products also utilize the company’s patented infusion technology to deliver federally legal hemp oil ingredients inside nutritious and tasty formulations that are free of the bitter taste typically associated with hemp. Products in this line include the Lexaria Energy Bar, a hemp oil-infused protein bar. Other nutritious products are in development for the Lexaria Energy line, with a focus on ensuring responsible production techniques and gluten-free formulations.”

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.lexariabioscience.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Buz Investors NetworkNewsWire Announces Publication NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals

$IMLFF Announces Publication of Discussion on the R&D of Cannabinoids

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use

Buz Investors NetworkNewsWire Announces Publication NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals

Buz Investors NetworkNewsWire Announces PublicationNetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF), an NNW client that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

The publication, entitled, “Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth,” discusses the rampant growth of the cannabis market and how a number of biotech companies are developing cannabinoid-based therapies to address unmet medical needs.




OTHER STORIESBUZ TRADERS FOLLOW

NetworkNewsWire Announces Publication

To view the full publication visit: https://www.networknewswire.com/biotech-innovations-drive-cannabinoid-based-pharmaceutical-market-growth/

“Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc.’s (IMLFF) flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). As of now, there is no cure for EB. INM-750 is the first treatment ever developed specifically for this disease that has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and possibly reverse the course of the disease through the modulating of keratins in the skin. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects.”

InMed’s pipeline is further discussed in the publication, alongside a look at several industry peers.

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.

For more information, visit www.inmedpharma.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and contributing writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://nnw.fm/Disclaimer



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )